Key result
A novel one-step real-time RT-PCR assay for SARS-CoV-2 demonstrated 100% sensitivity and 100% specificity in a cohort of 26 clinical samples, with a turnaround time of less than 2 hours.
Why the study?
Early diagnosis of SARS-CoV-2 infected patients is essential to control the dynamics of the COVID-19 pandemic.
Does a novel one-step multiplex real-time RT-PCR assay with automated analysis accurately detect SARS-CoV-2 in clinical samples?
Does a novel one-step multiplex real-time RT-PCR assay with automated analysis accurately detect SARS-CoV-2 in clinical samples?
A novel, low-cost, rapid one-step RT-PCR assay with automated analysis demonstrates high sensitivity and specificity for SARS-CoV-2 detection in a small initial cohort.
May aid rapid SARS-CoV-2 detection in labs; leaves open prospective clinical validation before routine use.
Early diagnosis of SARS-CoV-2 infected patients is essential to control the dynamics of the COVID-19 pandemic. We develop a rapid and accurate one-step multiplex TaqMan probe-based real-time RT-PCR assay, along with a computational tool to systematically analyse the data. Our assay could detect to a limit of 15 copies of SARS-CoV-2 transcripts—based on experiments performed by spiking total human RNA with in vitro synthesized viral transcripts. The assay was evaluated by performing 184 validations for the SARS-CoV-2 Nucleocapsid gene and human RNase P as an internal control reference gene with dilutions ranging from 1-100 ng for human RNA on a cohort of 26 clinical samples. 5 of 26 patients were confirmed to be infected with SARS-CoV-2, while 21 tested negative, consistent with the standards. The accuracy of the assay was found to be 100% sensitive and 100% specific based on the 26 clinical samples that need to be further verified using a large number of clinical samples. In summary, we present a rapid, easy to implement real-time PCR based assay with automated analysis using a novel COVID qPCR Analyzer tool with graphical user interface (GUI) to analyze the raw qRT-PCR data in an unbiased manner at a cost of under $3 per reaction and turnaround time of less than 2h, to enable in-house SARS-CoV-2 testing across laboratories.
No takes yet. Share an insight, caveat, or question.
Dharavath et al. (2020) studied SARS-CoV-2 infection (n=26). One-step multiplex TaqMan probe-based real-time RT-PCR assay vs. Standard testing was evaluated on Diagnostic sensitivity and specificity. A novel one-step real-time RT-PCR assay for SARS-CoV-2 demonstrated 100% sensitivity and 100% specificity in a cohort of 26 clinical samples, with a turnaround time of less than 2 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: